Re: Vold et al.: Canaloplasty and trabeculotomy with the OMNI system in pseudophakic patients with open-angle glaucoma: the ROMEO study REPLY

被引:35
作者
Vold, Steven D. [1 ]
Williamson, Blake K. [2 ]
Hirsch, Louis [3 ]
Aminlari, Ardalan E. [4 ]
Cho, Andrew S. [5 ]
Nelson, Cade [2 ]
Dickerson, Jaime E., Jr. [6 ,7 ]
机构
[1] Vold Vis, Fayetteville, AR USA
[2] Williamson Eye Ctr, Baton Rouge, LA USA
[3] Mercy Eye Specialists, Springfield, MO USA
[4] Morris Eye Grp, Encinitas, CA USA
[5] Serrano Eye Ctr Med Grp, Los Angeles, CA USA
[6] Univ North Texas, North Texas Eye Res Inst, Hlth Sci Ctr, 3716 Lands End St, Ft Worth, TX 76109 USA
[7] Sight Sci Inc, Menlo Pk, CA USA
来源
OPHTHALMOLOGY GLAUCOMA | 2021年 / 4卷 / 02期
关键词
ab interno; canaloplasty; MIGS; Minimally invasive glaucoma surgery; OMNI; open-angle glaucoma; Schlemm's canal; trabeculotomy; viscodilation;
D O I
10.1016/j.ogla.2020.10.001
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: Provide outcomes up to 12 months postsurgically for sequential canaloplasty and trabeculotomy with the OMNI surgical system (Sight Sciences, Inc) in pseudophakic patients with mild to moderate open-angle glaucoma. Design: Retrospective, multicenter, single-arm study conducted at 10 multi-subspecialty ophthalmology practices and surgery centers located in 7 states (Arkansas, California, Kansas, Louisiana, Missouri, New York, and Texas). Participants: Eligible patients were pseudophakic, with mild/moderate open-angle glaucoma, 12-month follow-up, and medicated intraocular pressure (IOP) ≤36 mmHg on ≤4 medications preoperatively. One eye per patient was enrolled. Methods: Institutional Review Board approved. All available cases meeting eligibility criteria were enrolled. Analysis of secondary end points was stratified by baseline (BL) IOP (>18 mmHg in group 1 and ≤18 mmHg in group 2) recognizing that treatment goals differed depending on BL IOP. Main Outcome Measures: Primary success was defined as the proportion of patients with ≥20% reduction in IOP from BL or IOP between 6 and 18 mmHg (inclusive) and on the same or fewer medications without secondary surgical intervention (SSI). Other effectiveness end points included mean IOP and number of medications at 12 months. Safety end points were best-corrected visual acuity (BCVA), adverse events (AEs), and SSIs. Results: Forty-eight patients were enrolled, 24 in each group. Primary success was met by 73%. Mean IOP was reduced in group 1 (21.8 to 15.6 mmHg, P < 0.0001) and remained controlled in group 2 (15.4 to 13.9 mmHg, P = 0.24). Medications went from 1.7 ± 1.3 to 1.2 ± 1.3 (P = 0.024) in group 1 and from 2.0 ± 1.3 to 1.3 ± 1.3 (P = 0.003) in group 2. Adverse events were typical for the patient population undergoing angle surgery. Those reasonably related to the procedure were mild inflammation (13%), IOP spikes (6%), hyphema, corneal edema, and BCVA loss (all 4%). Five patients (10%) required an SSI. Conclusions: The sequential combination of canaloplasty followed by trabeculotomy performed as stand-alone procedures using the OMNI system in pseudophakic patients with open-angle glaucoma provides effective IOP reduction or sustained IOP control and meaningful medication reduction for up to 12 months postoperatively. © 2020 American Academy of Ophthalmology
引用
收藏
页码:E6 / E7
页数:2
相关论文
共 31 条
[21]   Predictors of long-term progression in the early manifest glaucoma trial [J].
Leske, M. Cristina ;
Heijl, Anders ;
Hyman, Leslie ;
Bengtsson, Boel ;
Dong, LiMing ;
Yang, Zhongming .
OPHTHALMOLOGY, 2007, 114 (11) :1965-1972
[22]   PRESSURES IN THE JUXTACANALICULAR TISSUE AND SCHLEMM CANAL IN MONKEYS [J].
MAEPEA, O ;
BILL, A .
EXPERIMENTAL EYE RESEARCH, 1992, 54 (06) :879-883
[23]   Trabecular micro-bypass stent implantation during small-incision cataract surgery for open-angle glaucoma or ocular hypertension: Long-term results [J].
Neuhann, Tobias H. .
JOURNAL OF CATARACT AND REFRACTIVE SURGERY, 2015, 41 (12) :2664-2671
[24]   Intermediate Results of iStent or iStent inject Implantation Combined with Cataract Surgery in a Real-World Setting: A Longitudinal Retrospective Study [J].
Paletta Guedes, Ricardo Augusto ;
Gravina, Daniela Marcelo ;
Lake, Jonathan Clive ;
Paletta Guedes, Vanessa Maria ;
Chaoubah, Alfredo .
OPHTHALMOLOGY AND THERAPY, 2019, 8 (01) :87-100
[25]  
Rosenberg LF, 2016, OPHTHALMOLOGY, V123, pP4
[26]   Micro-invasive glaucoma surgery: current perspectives and future directions [J].
Saheb, Hady ;
Ahmed, Iqbal Ike K. .
CURRENT OPINION IN OPHTHALMOLOGY, 2012, 23 (02) :96-104
[27]   Prospective, Randomized, Controlled Pivotal Trial of an Ab Interno Implanted Trabecular Micro-Bypass in Primary Open-Angle Glaucoma and Cataract Two-Year Results [J].
Samuelson, Thomas W. ;
Sarkisian, Steven R., Jr. ;
Lubeck, David M. ;
Stiles, Michael C. ;
Duh, Yi-Jing ;
Romo, Eeke A. ;
Giamporcaro, Jane Ellen ;
Hornbeak, Dana M. ;
Katz, L. Jay .
OPHTHALMOLOGY, 2019, 126 (06) :811-821
[28]   Randomized Evaluation of the Trabecular Micro-Bypass Stent with Phacoemulsification in Patients with Glaucoma and Cataract [J].
Samuelson, Thomas W. ;
Katz, L. Jay ;
Wells, Jeffrey M. ;
Duh, Yi-Jing ;
Giamporcaro, Jane Ellen .
OPHTHALMOLOGY, 2011, 118 (03) :459-467
[29]   360° ab-interno trabeculotomy in refractory primary open-angle glaucoma [J].
Sarkisian, Steven R. ;
Mathews, Basil ;
Ding, Kai ;
Patel, Aashka ;
Nicek, Zachary .
CLINICAL OPHTHALMOLOGY, 2019, 13 :161-168
[30]  
US Food and Drug Administration, ISTENT TRAB MICR BYP